阿尔茨海默病的病理机制和治疗进展
Jingjing Zhang1, Guoqing Kong2, Jinyue Yang1
1Department of Neurology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China.
European journal of medical research
|July 14, 2025
概括
阿尔茨海默病 (AD) 研究强调了复杂的原因,如遗传学和新陈代谢. 有效的治疗需要针对多个途径和早期检测以获得更好的结果.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是全球痴呆的主要原因,其特征是粉样质斑块,团和神经炎症.
- 目前的治疗方法,包括抗粉样蛋白疗法,有效性和副作用有限,需要新的策略.
研究的目的:
- 审查阿尔茨海默病 (AD) 病理生理学,诊断和治疗方面的最新进展.
- 强调遗传,代谢和神经血管因素在AD的相互作用.
- 评估药理和非药理干预措施,包括个性化医学.
主要方法:
- 分子研究,动物模型和临床试验的系统审查.
- 对新出现的诊断生物标志物和神经成像技术进行批判性分析.
- 对定位,抗炎和生活方式干预措施的评估.
主要成果:
- 了解AD的发病因子涉及遗传风险因素 (例如,APOE ε4),蛋白质稳定,新陈代谢和神经血管健康.
- 新兴的生物标志物能够更早,更准确地检测AD.
- 针对各种病理过程的多式干预措施显示出有前途.
结论:
- 有效的阿尔茨海默病 (AD) 管理需要转向早期检测和组合疗法.
- 由于AD异质性,个性化医疗方法至关重要.
- 未来的研究应该专注于将多式联运战略转化为临床实践.
相关概念视频
Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
Parkinson's Disease: Overview
715
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
715
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
993
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
993
Dementia
169
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
169
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K


